THE PROGNOSTIC-SIGNIFICANCE OF CYTOGENETIC ABNORMALITIES IN MYELODYSPLASTIC SYNDROMES (MDS) FOLLOWING G-CSF

被引：0
|
作者：
LEBEAU, M
TAYLOR, K
LARSON, R
KOEFFLER, P
NEGRIN, R
SABA, H
GANSER, A
JAKUBOWSKI, A
GABRILOVE, J
MUFTI, GJ
CRUZ, J
LANGLEY, G
VARDIMAN, J
DAVIS, M
GREENBERG, P
机构：
[1] UNIV CHICAGO, CHICAGO, IL 60637 USA
[2] MATER HOSP, BRISBANE, AUSTRALIA
[3] UNIV CALIF LOS ANGELES, LOS ANGELES, CA USA
[4] MOFFITT CANC CTR, TAMPA, FL USA
[5] GOETHE UNIV, FRANKFURT, GERMANY
[6] MEM HOSP, ALBANY, NY USA
[7] UNIV LONDON KINGS COLL HOSP, LONDON SE5 8RX, ENGLAND
[8] WAKE FOREST CANC CTR, WINSTON SALEM, NC USA
[9] VICTORIA GEN HOSP, HALIFAX B3H 2Y9, NS, CANADA
[10] AMGEN INC, THOUSAND OAKS, CA USA
[11] STANFORD UNIV HOSP, STANFORD, CA 94305 USA
来源：
BLOOD | 1993年 / 82卷 / 10期
关键词：
D O I：
暂无
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
引用
收藏
页码：A375 / A375
页数：1
相关论文
共 50 条
  • [41] PROGNOSTIC SIGNIFICANCE OF CYTOGENETIC CATEGORIES IN MYELODYSPLASTIC SYNDROMES: SINGLE CENTRE STUDY FROM OMAN
    Fawaz, N.
    Alkindi, S.
    Huneini, M.
    Al Farsi, K.
    Al Khabori, M.
    Al Riyami, A.
    Dennison, D.
    Udayakumar, A.
    Panjwani, V.
    Pathare, A.
    HAEMATOLOGICA, 2014, 99 : 623 - 623
  • [42] Intensive chemotherapy combined with G-CSF and allogeneic bone marrow transplantation (BMT) in high risk myelodysplastic syndromes (MDS) or acute leukemia (AL) evolving from MDS
    Bernasconi, C
    Alessandrino, EP
    Bernasconi, P
    Bonfichi, M
    Caldera, D
    Lazzarino, M
    Canevari, A
    Brusamolino, E
    Pagnucco, G
    Castagnola, C
    BRITISH JOURNAL OF HAEMATOLOGY, 1996, 93 : 589 - 589
  • [43] Has cytogenetic evolution any prognostic relevance in myelodysplastic syndromes (MDS)? A study on 153 patients.
    Bernasconi, Paolo
    Klersy, Catherine
    Boni, Marina
    Cavigliano, Paola Maria
    Calatroni, Silvia
    Giardini, Ilaria
    Rocca, Barbara
    Zappatore, Rita
    Dambruoso, Irene
    Caresana, Marilena
    Lazzarino, Mario
    BLOOD, 2007, 110 (11) : 725A - 726A
  • [44] Topotecan, cytosine arabinoside and G-CSF (TAG) versus idarubicin, cytosine arabinoside and G-CSF (IDAG) in patients with myelodysplastic syndrome (MDS) or MDS in transformation: A randomised Phase III study.
    Guilhot, F
    Bouabdallah, R
    Desablens, B
    Guerci, A
    Ferrant, A
    Chopra, R
    Amrein, P
    Saba, H
    Dharan, B
    Gress, M
    Camlett, I
    Ross, G
    BLOOD, 2002, 100 (11) : 98A - 98A
  • [45] PROGNOSTIC VALUE OF THE FAB CLASSIFICATION FOR MYELODYSPLASTIC SYNDROMES (MDS)
    AUL, C
    FISCHER, JT
    HORSTKOTTE, D
    SCHNEIDER, W
    BLUT, 1984, 49 (03): : 246 - 246
  • [46] G-CSF: increased risk of myelodysplastic syndrome?
    Reactions Weekly, 2002, 919 (1) : 3 - 3
  • [47] Erythropoietin (rHuEpo) plus G-CSF in the treatment of anemia in myelodysplastic syndromes (MDS): Results of a randomised trial with impact on quality of life and costs.
    Casadevall, N
    Durieux, P
    Dubois, S
    Lepage, E
    Hemery, F
    Quarre, MC
    Fenaux, P
    Damaj, G
    Giraudier, S
    Guerci, A
    Laurent, G
    Dombret, H
    Stamatoullas, A
    Vekhoff, A
    Ribrag, V
    Dreyfus, F
    BLOOD, 2001, 98 (11) : 848A - 848A
  • [48] EXPRESSION OF CD34 AND P-GLYCOPROTEIN - PROGNOSTIC-SIGNIFICANCE IN PRIMARY MYELODYSPLASTIC SYNDROMES
    RUNDE, V
    GERMING, U
    AUL, C
    INTERNATIONAL JOURNAL OF ONCOLOGY, 1995, 7 (04) : 901 - 905
  • [49] PRIMARY MYELODYSPLASTIC SYNDROMES - DIAGNOSTIC AND PROGNOSTIC-SIGNIFICANCE OF IMMUNOHISTOCHEMICAL ASSESSMENT OF BONE-MARROW BIOPSIES
    MANGI, MH
    MUFTI, GJ
    BLOOD, 1992, 79 (01) : 198 - 205
  • [50] CHROMOSOME ANALYSES IN PATIENTS WITH MYELODYSPLASTIC SYNDROMES - CORRELATION WITH BONE-MARROW HISTOPATHOLOGY AND PROGNOSTIC-SIGNIFICANCE
    WERNER, M
    MASCHEK, H
    KALOUTSI, V
    CHORITZ, H
    GEORGII, A
    VIRCHOWS ARCHIV A-PATHOLOGICAL ANATOMY AND HISTOPATHOLOGY, 1992, 421 (01) : 47 - 52
12345